Overcoming Barriers to Use of SGLT2 Inhibitor Therapy: The Battle Against Clinical Inertia
- PMID: 37318416
- DOI: 10.1016/j.jchf.2023.05.006
Overcoming Barriers to Use of SGLT2 Inhibitor Therapy: The Battle Against Clinical Inertia
Keywords: Veterans Affairs; cost; guideline-directed medical therapy; heart failure; sodium-glucose cotransporter-2 inhibitor.
Conflict of interest statement
Funding Support and Author Disclosures Dr Greene has received research support from the Duke University Department of Medicine Chair’s Research Award, the American Heart Association (#929502), Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards for Amgen, AstraZeneca, Boehringer Ingelheim/Lilly, Bristol Myers Squibb, Cytokinetics, Roche Diagnostics, Sanofi, and scPharmaceuticals; has served as a consultant for Amgen, Bayer, Bristol Myers Squibb, Boehringer Ingelheim/Lilly, CSL Vifor, Merck, PharmaIN, Roche Diagnostics, Sanofi, Tricog Health, and Urovant Pharmaceuticals; and has received speaker fees from Boehringer Ingelheim, Cytokinetics, and Roche Diagnostics. Dr Pierce has reported that he has no relationships relevant to the contents of this paper to disclose.
Comment on
-
Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs.JACC Heart Fail. 2023 Aug;11(8 Pt 1):933-942. doi: 10.1016/j.jchf.2023.03.024. Epub 2023 May 17. JACC Heart Fail. 2023. PMID: 37204363
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
